This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Valeant, Salix Pharma file paperwork with US antitrust regulator

( March 4, 2015, 14:35 GMT | Official Statement) -- MLex Summary: Specialty pharmaceutical company Valeant Pharmaceuticals International and Salix Pharmaceuticals filed paperwork seeking US antitrust approval for their planned $158-per-share deal on Feb. 27 and March 2, respectively, according to a filing with the US Securities and Exchange Commission by Salix on Wednesday. The antitrust authorities have 15 days to approve the deal or issue a request for additional information. It's estimated the initial review period will expire on March 17 unless terminated earlier by antitrust enforcers or extended by a 'second request.'Extract....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login